As CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats–Cas9) and other gene-editing technologies hasten the feasibility of effective somatic and germline genomic manipulation, an international panel of genetics groups has weighed in on some of the thorniest ethical and scientific implications facing clinical use of gene editing.

Led by the American Society of Human Genetics (ASHG), 11 organizations published a joint statement in August concentrating on the prospects for germline alteration, a no-fly zone among molecular biologists since the dawn of gene therapy in the 1980s. The ASHG-sponsored statement was drafted by a committee of representatives from the UK Association of Genetic Nurses and Counsellors, Canadian Association of Genetic Counsellors, the International Genetic Epidemiological Society, and the US National Society of Genetic Counselors, as well as the ASHG. The final document was endorsed by these groups and 6 other international medical or genetics associations.

随着CRISPR / Cas9（聚簇的定期回文的短回文重复序列-Cas9）和其他基因编辑技术提高了有效的体细胞和种系基因组操作的可行性，国际遗传学小组评估了所面临的一些最棘手的伦理和科学含义基因编辑的临床使用。

由美国人类遗传学会（ASHG）领导的11个组织在8月发表了一份联合声明，着眼于种系改变的前景，这是自1980年代基因疗法问世以来分子生物学家禁飞的区域。由ASHG赞助的声明是由英国遗传护士和参赞者协会，加拿大遗传参赞者协会，国际遗传流行病学会，美国国家遗传参赞者协会以及ASHG的代表委员会起草的。这些组织和其他6个国际医学或遗传学协会认可了最终文件。